Cinagrit 75 Tablet contains Cinnarizine 75mg, a selective antihistaminic and calcium channel blocker that helps manage vertigo, motion sickness, and balance disorders. It improves microcirculation in the inner ear and brain, stabilizing the vestibular system and reducing symptoms like dizziness, nausea, and imbalance.
It is particularly beneficial for patients suffering from peripheral vertigo, Meniere’s disease, and motion-induced nausea, providing fast and reliable relief. Regular use under medical guidance helps reduce the frequency and intensity of vertigo episodes, making it a preferred prescription in neurology and ENT practice.
This tablet belongs to the neurology and ENT segment, ensuring high demand in hospitals, clinics, and specialty pharmacies. Its efficacy, safety profile, and patient-friendly nature make it an excellent choice for PCD pharma franchise partners, institutional supply, and third-party manufacturing.
With increasing awareness about balance disorders and motion sickness, Cinagrit 75 Tablet offers a lucrative B2B opportunity for pharma distributors and franchisees. It can also cater to international markets where motion sickness and geriatric vertigo are common, making it a high-demand, high-margin addition to any pharma portfolio.